This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Bansal P , Osman D , Gan GN , Simon GR , Boumber Y
Recent Advances in Immunotherapy in Metastatic NSCLC
Front Oncol. 2016 ;6 :239
PMID: 27896216 PMCID: PMC5107578 URL: https://www.ncbi.nlm.nih.gov/pubmed/27896216
AbstractNon-small cell lung cancer (NSCLC) is one of most common malignancies and the leading cause of cancer deaths worldwide. Despite advances in targeted therapies, majority of NSCLC patients do not have targetable genomic alterations. Nevertheless, recent discovery that NSCLC is an immunogenic tumor type, and several breakthroughs in immunotherapies have led to rapid expansion of this new treatment modality in NSCLC with recent FDA approvals of programed death receptor-1 inhibitors, such as nivolumab and pembrolizumab. Here, we review promising immunotherapeutic approaches in metastatic NSCLC, including checkpoint inhibitors, agents with other mechanisms of action, and immunotherapy combinations with other drugs. With advent of immunotherapy, therapeutic options in metastatic NSCLC are rapidly expanding with the hope to further expand life expectancy in metastatic lung cancer.
NotesBansal, Pranshu Osman, Diaa Gan, Gregory N Simon, George R Boumber, Yanis Review Journal Article Switzerland Front Oncol. 2016 Nov 14;6:239. eCollection 2016.